NeuroDerm Ltd. Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease
6/19/2013 10:34:35 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NESS ZIONA, Israel, June 19, 2013 -- /PRNewswire/ --
NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, were presented at the 2013 International Congress of Parkinson's Disease and Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations.
Read more here: http://www.sacbee.com/2013/06/19/5508091/neuroderm-announces-presentation.html#storylink=cpy
Help employers find you! Check out all the jobs and post your resume.